📊 ENVB Key Takeaways
Is Enveric Biosciences, Inc. (ENVB) a Good Investment?
Enveric Biosciences faces severe operational distress evidenced by negative revenue (-303.00, -148.4% YoY decline) and persistent operating cash burn of -2.3M annually. While the company maintains exceptional liquidity with 4.9M cash and low leverage, this liquidity masks fundamental business failure requiring immediate operational turnaround or capital restructuring.
Enveric Biosciences shows extremely weak fundamentals: revenue is effectively nonexistent, operating losses remain large relative to its asset base, and free cash flow is deeply negative. While the balance sheet currently shows solid near-term liquidity, the company’s cash burn and lack of durable commercial revenue make the business fundamentally fragile without external financing or a major operating turnaround.
Enveric Biosciences, Inc. Key Strengths (ENVB)
- Exceptional liquidity position with 11.67x current ratio and 4.9M cash reserves (89% of total assets)
- Conservative capital structure with low leverage (0.15x debt/equity ratio) and manageable long-term debt of 740.3K
- Year-over-year improvement in losses (net income loss narrowing by 26.7% and diluted EPS improving by 84.1%)
- Cash of $3.76M supports near-term operations better than many micro-cap biotech peers
- Current and quick ratios of 4.60x indicate limited immediate liquidity stress
- Debt load is modest relative to equity, with debt/equity of 0.21x
ENVB Stock Risks: Enveric Biosciences, Inc. Investment Risks
- Negative revenue of -303.00 with -148.4% YoY deterioration indicates fundamental business failure, likely from refunds/returns exceeding sales
- Persistent negative operating cash flow of -2.3M annually combined with negative operating income of -1.6M demonstrates non-sustainable business model
- Cash runway of approximately 2+ years at current burn rate, insufficient for pharmaceutical sector requiring long R&D cycles and regulatory approvals
- Zero insider Form 4 filings in 90 days suggests lack of insider confidence in company direction
- Revenue collapsed 94.1% YoY to just $144, indicating no meaningful operating scale or revenue stability
- Operating loss of $6.58M and negative free cash flow of $6.36M imply continued heavy cash consumption
- Very small asset base and negative returns on equity/assets suggest weak financial resilience if funding conditions tighten
Key Metrics to Watch
- Revenue stabilization and return to positive sales figures
- Operating cash flow inflection point above zero
- Cash burn rate trajectory and time to cash depletion at current burn rate
- Quarterly operating cash burn relative to cash balance
- Any sustained revenue generation or commercialization progress
Enveric Biosciences, Inc. (ENVB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 746,540.9% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 11.67x current ratio provides a solid financial cushion.
ENVB Profit Margin, ROE & Profitability Analysis
ENVB vs Healthcare Sector: How Enveric Biosciences, Inc. Compares
How Enveric Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Enveric Biosciences, Inc. Stock Overvalued? ENVB Valuation Analysis 2026
Based on fundamental analysis, Enveric Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Enveric Biosciences, Inc. Balance Sheet: ENVB Debt, Cash & Liquidity
ENVB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Enveric Biosciences, Inc.'s revenue has declined by 12% over the 5-year period, indicating business contraction. The most recent EPS of $-228.48 indicates the company is currently unprofitable.
ENVB Revenue Growth, EPS Growth & YoY Performance
ENVB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2020 | $8.5M | $41.3K | $-0.03 |
| Q2 2020 | $8.3M | -$1.3M | $-0.48 |
| Q1 2020 | $9.6M | -$1.8M | $-0.60 |
| Q3 2019 | $9.1M | $41.3K | $0.00 |
| Q2 2019 | $11.0M | -$1.3M | $-0.03 |
| Q1 2019 | $10.7M | -$1.6M | $-0.04 |
| Q3 2018 | $10.6M | $388.7K | $0.02 |
| Q2 2018 | $11.1M | -$1.3M | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Enveric Biosciences, Inc. Dividends, Buybacks & Capital Allocation
ENVB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Enveric Biosciences, Inc. (CIK: 0000890821)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ENVB
What is the AI rating for ENVB?
Enveric Biosciences, Inc. (ENVB) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ENVB's key strengths?
Claude: Exceptional liquidity position with 11.67x current ratio and 4.9M cash reserves (89% of total assets). Conservative capital structure with low leverage (0.15x debt/equity ratio) and manageable long-term debt of 740.3K. ChatGPT: Cash of $3.76M supports near-term operations better than many micro-cap biotech peers. Current and quick ratios of 4.60x indicate limited immediate liquidity stress.
What are the risks of investing in ENVB?
Claude: Negative revenue of -303.00 with -148.4% YoY deterioration indicates fundamental business failure, likely from refunds/returns exceeding sales. Persistent negative operating cash flow of -2.3M annually combined with negative operating income of -1.6M demonstrates non-sustainable business model. ChatGPT: Revenue collapsed 94.1% YoY to just $144, indicating no meaningful operating scale or revenue stability. Operating loss of $6.58M and negative free cash flow of $6.36M imply continued heavy cash consumption.
What is ENVB's revenue and growth?
Enveric Biosciences, Inc. reported revenue of $-303.0.
Does ENVB pay dividends?
Enveric Biosciences, Inc. does not currently pay dividends.
Where can I find ENVB SEC filings?
Official SEC filings for Enveric Biosciences, Inc. (CIK: 0000890821) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ENVB's EPS?
Enveric Biosciences, Inc. has a diluted EPS of $-1.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ENVB's fundamental grade?
Based on our AI fundamental analysis in June 2026, Enveric Biosciences, Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ENVB stock overvalued or undervalued?
Valuation metrics for ENVB: ROE of -32.3% (sector avg: 15%), net margin of 539,100.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ENVB's AI grade for 2026?
Our dual AI analysis gives Enveric Biosciences, Inc. a combined D grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ENVB's free cash flow?
Enveric Biosciences, Inc.'s operating cash flow is $-2.3M, with capital expenditures of $5.2K. FCF margin is 746,540.9%.
How does ENVB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 539,100.0% (avg: 12%), ROE -32.3% (avg: 15%), current ratio 11.67 (avg: 2).